{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T23:58:02Z","timestamp":1777766282838,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,9,8]],"date-time":"2009-09-08T00:00:00Z","timestamp":1252368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,9,8]],"date-time":"2009-09-08T00:00:00Z","timestamp":1252368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"abstract":"<jats:p>The in vitro activities of azlocillin, carbenicillin, ceftriaxone, piperacillin, N-formimidoyl thienamycin (N-f thienamycin) and tobramycin have been compared against clinical isolates of Pseudomonas aeruginosa (n = 100) and Acinetobacter calcoaceticus (n = 50). An agar dilution method was employed for measurement of minimal inhibitory concentration (MIC). Tobramycin was the most active drug against P. aeruginosa (MIC\u22642 mg\/l). Of the \u03b2-lactam antibiotics, N-f thienamycin showed the highest activity, and carbenicillin was least active. Both N-f thienamycin and tobramycin were highly active against A. calcoaceticus (MIC\u2264 mg\/l), although one isolate was resistant to tobramycin (MIC &gt; 16 mg\/l). The other drugs were only moderately active against A. calcoaceticus.<\/jats:p>","DOI":"10.1159\/000238216","type":"journal-article","created":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T09:21:59Z","timestamp":1252488119000},"page":"332-336","source":"Crossref","is-referenced-by-count":3,"title":["Pseudomonas aeruginosa and Acinetobacter calcoaceticus: In vitro Susceptibility of 150 Clinical Isolates to Five \u03b2-Lactam Antibiotics and Tobramycin"],"prefix":"10.1159","author":[{"given":"William L.","family":"Dibb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibecke","family":"Asphaug Kjellevold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asbj\u00f8rn","family":"Digranes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,9,8]]},"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/238216","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000238216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:32:52Z","timestamp":1777476772000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000238216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,8]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000238216","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,8]]}}}